BD0801

DRUG2 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorOvarian Cancer

Phase 2

A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

TerminatedNCT05148195

Jiangsu Simcere Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2021-12-22End: 2023-07-26Updated: 2024-03-13

Phase 3

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

CompletedNCT04908787

Jiangsu Simcere Pharmaceutical Co., Ltd.Ovarian Cancer

Start: 2021-06-11End: 2024-10-11Updated: 2025-09-11

Related Papers

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

2026-01-09

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.

Journal of Clinical Oncology2025-05-28

Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.

2025-01-302 citations

The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study.

2025-01-21

A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

Journal of Clinical Oncology2024-06-051 citations